Why leading medical device companies choose Neuron7 for service AI

A cardiologist would never prescribe treatment from symptoms alone.

Before recommending anything, they read the blood work. They pull the imaging, the patient history, the genetics, the clinical literature — and reason across all of it before they act. Symptoms tell you something is wrong. They rarely tell you why, or what to do about it.

Determining how to resolve an issue on a critical device is the same kind of decision. It’s the most important call in service — and in medical devices, it’s a decision that eventually reaches a patient.

In service, the machine logs are the blood work. Telemetry, error codes, case history, service manuals, engineering updates, known defects, configuration data — each is a diagnostic signal. Read one in isolation and you get a guess. Read them together and the root cause, and the resolution path, often change entirely.

That’s the bar for complex medical device service. And it’s exactly where generic AI falls short: asked to resolve a critical device issue from the symptom alone, it does what a good clinician never would — it prescribes without the labs.

The companies that service the most complex medical equipment in the world figured this out. Then they chose the platform built for how the decision actually gets made.

Let’s start with where things stand.

Neuron7 is live across medical device companies spanning eight distinct service categories: hospital automation, clinical lab diagnostics, diagnostic imaging, sterile processing, endoscopy and surgical imaging, radiation oncology, interventional cardiology, and diabetes care. These aren’t evaluations. They’re production deployments — running on the service organizations of companies that service 2,300-plus hospitals, run the world’s largest clinical reference labs, treat cancer with multi-million-dollar radiation therapy systems, and support the interventional cardiology procedures happening in operating rooms right now.

TransLogic. Karl Storz. Philips. Terumo BCT. Boston Scientific. Accuray. STERIS. Medtronic. Dexcom. To name a few.

That roster didn’t happen because we have a great pitch. It happened because the platform does things other platforms don’t.

Here’s what it does — and why it matters more in medical devices than anywhere else we sell.

The platforms that failed first

Before we talk about the product, it’s worth being direct about why the category needed it.

Medical device companies have tried generic AI. They’ve tried RAG-based platforms that search knowledge bases and return probable answers. They’ve tried horizontal platforms built for broad customer service that were repurposed for technical field service. They’ve tried the “AI features” baked into their existing CRM and FSM platforms by vendors who didn’t want to be left out of the AI moment.

The pattern is consistent enough that we can describe it before a customer tells us what happened.

The AI reaches 40 to 50% accuracy and stops. Technicians start working around it. Within 90 days, the platform is open in a tab nobody looks at. The service leader explains to their board that the AI “wasn’t mature enough for our use case.”

The diagnosis they give is usually wrong. It wasn’t the algorithm that failed. It was the foundation. To put it in the terms above: generic AI didn’t misread the symptom — it never ran the labs.

Generic AI has three structural failure modes in medical device service environments:

It learns from bad data. The average medical device service organization documents root cause in fewer than 40% of cases. Parts traceability sits below 30%. A generic AI model trained on that data learns the vagueness. “Replaced board, issue resolved” teaches the model almost nothing about the failure mode, the diagnostic sequence, or whether the repair addressed the root cause. The AI hallucinates specificity it was never given.

It doesn’t understand service data structure. Service data isn’t a knowledge base. It’s millions of semi-structured case notes, error codes, part numbers, technician observations, and engineering escalations — written in the compressed shorthand of people who’ve been doing this job for 15 years. A generic LLM treats a case note the same way it treats a Wikipedia article. It misses the signal. It can’t distinguish between a firmware-induced voltage fault and the same error code caused by a hardware failure on the same device, because it doesn’t understand the product model or the failure mode context.

It has no feedback loop. Without a mechanism that captures whether a technician accepted, modified, or rejected a resolution — and feeds that signal back into the model — generic AI can’t improve. Every interaction starts from zero. The accuracy that wasn’t there at deployment isn’t there at month 12.

These aren’t complaints about AI. They’re architectural observations. They’re why we built the platform the way we built it.

The four things we built that nobody else has

AI Readiness scoring

Before we deploy resolution intelligence, we score the data it’s going to learn from.

The Resolution Quality Index evaluates every case record across seven dimensions: root cause clarity, resolution sequence, parts traceability, model specificity, reusability, validation steps, and evidence strength. Every case gets a score from zero to one hundred. Technicians see their score at case closure and receive specific, actionable coaching — not “add more detail,” but “this note is missing root cause for the voltage regulator fault. What caused the failure?” — before they save.

At one medical device company, this changed the trajectory of the deployment. Years of case history that looked complete on the surface had a Resolution Quality Index that told a different story. The coaching loop transformed the data quality over weeks. And as the data quality improved, the resolution accuracy improved automatically — compounding. 96% accuracy. Three hours to three seconds.

No other service AI platform scores the data before it learns from it. Most don’t score it at all.

Deterministic resolution pathways

For known failure modes — issues that have been resolved dozens of times across the deployed fleet — Neuron7 delivers a deterministic answer. Not “here are three possible resolutions.” One resolution, pulled from validated sources, double-checked by SMEs, with the source traceable and the reasoning auditable.

This distinction is not about preference. It’s about regulatory reality.

Post-market surveillance requirements. JCAHO audits. MEMP documentation. Service events that are, by regulation, traceable. In a medical device service environment, a probabilistic AI recommendation is a compliance liability. A validated, auditable pathway is a compliance asset.

A company that develops surgical OR suites deployed deterministic pathways across their Human Medicine service organization, spanning 20-plus surgical specialties. They built the intelligence foundation before the install base grew, not after. The result: 20% fewer dispatches, because they scaled Neuron7 across remote support — giving those on the phone the collective intelligence of their best techs.

Log and device analysis

Your devices are already generating the earliest signals of failure. Error logs. Component voltage sequences. Operational patterns. Every major imaging system, clinical lab analyzer, and surgical imaging platform in service today produces this data.

The problem has never been the data. It’s been the connection.

Device diagnostic logs live in one system. Service case history lives in another. A technician arrives at a fault code drawing on memory and procedure manuals, not on the accumulated resolution intelligence of every engineer who diagnosed the same issue on the same product model.

Log analysis closes that gap. Neuron7 maps device diagnostic data against the Service Decision Graph — the full history of how similar faults have been resolved, at the product model level, across every deployment in the network. The device has been talking the whole time. This is the blood work — and the service organization can finally read it.

Company C deployed this capability across their North American field service organization — more than 2,000 field service engineers supporting MRI, CT, ultrasound, and image-guided therapy systems. Tier 0 and Tier 1 intelligent predictions are live. The FSM expansion is in progress.

Predictive service for non-connected equipment

Most predictive maintenance tools require connectivity. Live telemetry. Sensor data streaming. The model trains on the signal and surfaces anomalies before they become failures.

It’s a sound architecture — until you consider that roughly 80% of medical equipment in service today isn’t connected to anything.

Neuron7 predicts failures on non-connected equipment. The Service Decision Graph holds failure signature data for every product model: what the early symptoms look like before a component fails, at what usage thresholds failure events cluster, and which environmental factors correlate with accelerated degradation. That intelligence doesn’t require a live sensor. It requires the data every medical device company already has — captured in a graph for humans and AI to access.

Across our clinical lab diagnostics and sterile processing deployments, we’re building toward predictive capability that covers equipment that will never be connected to a live telemetry feed. The prediction comes from understanding what the failure history says, not from reading what the sensor is saying right now.

Why the roster exists

None of those customers showed up because we had a good demo.

They showed up because they’d tried other things. They’d watched generic AI plateau at 50% accuracy. They’d watched their technicians route around a platform that wasn’t reliable enough to trust. They’d seen what happens when an AI platform learns from bad data — you get a faster way to deliver the wrong answer.

They took the meeting because the problem wasn’t getting better. They deployed because the platform did something they hadn’t seen before: it scored the data, enforced deterministic pathways, connected the device logs, and predicted failures on equipment that nobody else could predict.

Where we’re going

The destination isn’t just a better version of what medical device service looks like today.

It’s a service organization where failures are predicted before they reach the patient. Where the knowledge of every engineer who ever resolved an issue survives their retirement. Where a technician on day one has access to the accumulated intelligence of a 20-year veteran — because that intelligence lives in the platform, not in the veteran’s memory.

And eventually, a service organization that can stand behind outcomes. Contracts built around uptime. Renewals based on actual asset performance. Autonomous agents resolving the busy work your techs hate. The kind of commitment that only becomes possible when the accuracy is high enough to trust, the data is clean enough to act on, and the prediction is reliable enough to schedule around.

We’re building that infrastructure.

If you’re running service operations in medical devices and you want to see where you fit in this — what your existing data scores, what the product looks like for your specific equipment category, and what a path from your current state to that destination looks like — we’d welcome that conversation.